PO12 - Acquired Hemophilia A: Case series

Wednesday, June 28, 2023

13:00 – 14:00 ET

Room: 10

Presenting Author(s)

Erik A. Vardumyan, Jr.

MD
Armenian Hemophilia and Thrombosis Treatment center
Yerevan, Yerevan, Armenia

Co-Author(s)

Nelli S. Sargsyan

MD
Armenian Hemophilia and Thrombosis Treatment center
Yerevan, Yerevan, Armenia
LH

Liana Hambardzumyan, Phd

MD
Armenian Hemophilia and Thrombosis Treatment center
Yerevan, Yerevan, Armenia
SP

Sona V. Petrosyan

MD, PhD
Armenian Hemophilia and Thrombosis Treatment center
Yerevan, Yerevan, Armenia
KA

Karine Arustamyan

Deputy director on sciense, Reaserch Center of maternal and Child Health Protection
Armenian Hemophilia and Thrombosis Treatment center
Yerevan, Yerevan, Armenia
GT

Gevorg N. Tamamyan

Head of the Department of Pediatric Oncology and Hematology, Yerevan State Medical University
Armenian Hemophilia and Thrombosis Treatment center
Yerevan, Yerevan, Armenia
AH

Armine Harutyunyan

Head of the Department of Obstetrics and Gynecology, Yerevan State Medical University,
Armenian Hemophilia and Thrombosis Treatment center
Yerevan, Wisconsin, United States
IK

Inga Karapetyan

MD, PhD
Armenian Hemophilia and Thrombosis Treatment center
Yerevan, Yerevan, Armenia
SD

Samvel Danelyan

Head of the Hematology center after Prof. R.Yeolyan
Armenian Hemophilia and Thrombosis Treatment center
Yerevan, Yerevan, Armenia
Heghine S. Khachatryan, MD, PhD

Head of Hemophilia and Thrombosis Center
Armenian Hemophilia and Thrombosis Treatment center
Yerevan, Yerevan, Armenia

Background: Acquired Hemophilia A(AHA) is an autoimmune disorder
characterized by the presence of endogenous Factor VIII autoantibodies
(inhibitors) in blood plasma. AHA is often diagnosed in older individuals and
is associated with other clinical conditions such as pregnancy, autoimmune
diseases, infections, respiratory disorders and drugs.

Aims: The main objective of this paper is to show the incidence of
AHA in Armenia in the last 10 years and correlation with other clinical
conditions.

Methods: Retrospective review of patients diagnosed with AHA. Including
patients who have positive serum autoantibodies against Factor VIII and
associated clinical conditions.

Results: According to inclusion criterias 5 patients were included. Mean
age of diagnosis of patients is 40. All the patients had clinical remission
after the treatment.

Conclusion(s): We observed a tendency to increase incidence of AHA. Our
paper suggests a high association of AHA and pregnancy. We also
observed that initial values of aPTT and Factor VIII activity do not have a
prognostic value. Treatment therapies in Armenia and its effectiveness
depends on the patients age and obstetric anamnesis. Therefore it is more
effective the steroid therapy among young patients. Partial or total clinical
remission observed in all 5 patients was due to steroid therapy